Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout

Benzinga_recent_news01-13

Aclarion, Inc. (NASDAQ:ACON) stock rose Tuesday after the company disclosed the closing of a $10.4 million common-stock financing priced at $5.18 per share. The clean, equity-only raise boosts the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603635775?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/13/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-13 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603635775","market":"us","top_or_hot":-1,"title":"Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout","media":"Benzinga_recent_news","content":"<div>\n<p>Aclarion, Inc. (NASDAQ:ACON) stock rose Tuesday after the company disclosed the closing of a $10.4 million common-stock financing priced at $5.18 per share.\nThe clean, equity-only raise boosts the ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 23:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aclarion, Inc. (NASDAQ:ACON) stock rose Tuesday after the company disclosed the closing of a $10.4 million common-stock financing priced at $5.18 per share.\nThe clean, equity-only raise boosts the ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACON","symbol_name":"ACLARION, INC","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout","article_id":"2603635775","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/13/Ipo-Initial-Public-Offering--Business-Ma.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49879642/aclarion-raises-10-4-million-sharpens-focus-on-nociscan-rollout","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603635775","pubTimestamp":1768319460,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance sheet & extending cash runway to 2028.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACON":"ACLARION, INC","BK4167":"医疗保健技术"},"translate_title":"Aclarion筹集1040万美元，更加关注Nociscan的推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACON":1},"content_text":"Aclarion, Inc. (NASDAQ:ACON) stock rose Tuesday after the company disclosed the closing of a $10.4 million common-stock financing priced at $5.18 per share.\nThe clean, equity-only raise boosts the company’s balance sheet, extends operating runway beyond key near- and mid-term milestones, and enhances strategic flexibility as Nociscan gains clinical and commercial traction.\nAs of January 12, 2026, the company had cash of $21.6 million, with zero debt. With this, the company’s cash runway extended into 2028 based on current operating plans.\nThe company plans to pursue further clinical validation by speeding up enrollment in the CLARITY trial, targeting roughly 25% patient enrollment by the end of the second quarter of 2026, with an initial internal analysis following completion of the first cohort’s three-month follow-up.\nAlso, Aclarions aims to complete and publish several investigator-led real-world evidence studies, broaden access across leading MRI platforms to expand the global market opportunity by more than 30%, and increase clinician awareness through greater participation in society-sponsored CME programs.\nThe company will also enhance scalability by improving workflow integration with the planned launch of Nociscan version 2.8 in the first quarter, while actively engaging with multiple U.S. commercial payers to evaluate and advance broader reimbursement for Nociscan.\nBrent Ness, Chief Executive Officer of Aclarion, stated, “With a debt-free balance sheet, strong cash reserves, and extended cash runway into 2028, we are focused squarely on execution, expanding adoption of Nociscan, deepening clinical evidence, and building strategic relationships that drive durable growth for patients, providers, payers, and shareholders.”\nLast week, the company reported strong adoption of its proprietary Nociscan AI-augmented platform in 2025, with annual scan volumes rising 69% year over year.\nFourth-quarter scan volumes increased 114% from the prior year, marking the third consecutive quarter of growth across U.S., U.K., and European sites.\nACON Price Action: Aclarion shares were down 5.21% at $4.27 at the time of publication on Tuesday. The stock is trading at a new 52-week low, according to Benzinga Pro data.\nImage via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603635775","isCrawlerRequest":true}